Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Margaret E. Nartea"'
Autor:
John M. Pagel, Oliver W. Press, Brenda Sandmaier, Brian G. Till, Ajay K. Gopal, Damian J. Green, K. Dane Wittrup, Kelly D. Orcutt, D. Scott Wilbur, Donald K. Hamlin, Ethan R. Balkin, Darrell R. Fisher, Mark D. Hylarides, Alexandra H. Hernandez, Margaret E. Nartea, Rosario Guel, Shyril O'Steen, Yukang Lin, Aimee L. Kenoyer, Johnnie J. Orozco
Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18cb196c04e590eb312858a4d9061fed
https://doi.org/10.1158/1535-7163.c.6542662
https://doi.org/10.1158/1535-7163.c.6542662
Autor:
John M. Pagel, Oliver W. Press, Brenda Sandmaier, Brian G. Till, Ajay K. Gopal, Damian J. Green, K. Dane Wittrup, Kelly D. Orcutt, D. Scott Wilbur, Donald K. Hamlin, Ethan R. Balkin, Darrell R. Fisher, Mark D. Hylarides, Alexandra H. Hernandez, Margaret E. Nartea, Rosario Guel, Shyril O'Steen, Yukang Lin, Aimee L. Kenoyer, Johnnie J. Orozco
Supplementary Materials, Methods and relevant AA sequences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c057d8965675ca7f790ca8236eb48a
https://doi.org/10.1158/1535-7163.22520518.v1
https://doi.org/10.1158/1535-7163.22520518.v1
Autor:
Frederick R. Appelbaum, Oliver W. Press, Brenda M. Sandmaier, Phuong Vo, Rainer Storb, John M. Pagel, Johnnie J. Orozco, Robyn Haaf, Ted Gooley, Joseph G. Rajendran, Ajay K. Gopal, Margaret E. Nartea, Damian J. Green, Darrell R. Fisher
Publikováno v:
Haematologica
Outcomes of patients with persistent high-risk leukemia or myelodysplasia prior to allogeneic hematopoietic cell transplantation are dismal. We therefore conducted a phase I trial evaluating the use of CD45-targeted radiotherapy preceding hematopoiet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86b89e6b58d1a1abacb307c8f1fdba80
http://europepmc.org/articles/PMC7271581
http://europepmc.org/articles/PMC7271581
Autor:
Heather A. Rasmussen, Sandra Kanan, Hilary Coye, Andrew J. Cowan, Edward N. Libby, Jonathan R. Fromm, Chaitra S. Ujjani, Ryan C. Lynch, Mazyar Shadman, Mary Philip, Sanaz Behnia, Edus H. Warren, Stephen D. Smith, Margaret E. Nartea, Ryan D. Cassaday, Andrei R. Shustov, Karolyn K. Morris, Christen N. Martino, Jenna M. Voutsinas, Brian G. Till, Ajay K. Gopal
Publikováno v:
Blood. 136:16-18
Background: Classical Hodgkin lymphoma (CHL) patients (pts) requiring second line therapy may still be cured with multiagent salvage chemotherapy followed by autologous stem cell transplant (ASCT). The likelihood of long-term remission following ASCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823f974d9948a29958e750103d2509d7
https://doi.org/10.1182/blood-2020-133763
https://doi.org/10.1182/blood-2020-133763
Autor:
Yukang Lin, Johnnie J. Orozco, Donald K. Hamlin, Brenda M. Sandmaier, Ted Gooley, Sherilyn A. Tuazon, Aimee L. Kenoyer, Margaret E. Nartea, Jon C. Jones, Ajay K. Gopal, Shyril O'Steen, Oliver W. Press, Brian W. Miller, Brian G. Till, D. Scott Wilbur, Damian J. Green, Melissa L. Comstock
Publikováno v:
Blood
Minimal residual disease (MRD) has become an increasingly prevalent and important entity in multiple myeloma (MM). Despite deepening responses to frontline therapy, roughly 75% of MM patients never become MRD-negative to ≤10(−5), which is concern
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91312884cd9ec7cf086f4e4ae5c7b51a
https://doi.org/10.1182/blood.2019001250
https://doi.org/10.1182/blood.2019001250
Autor:
Ted Gooley, Brenda M. Sandmaier, John M. Pagel, Johnnie J. Orozco, Sherilyn A. Tuazon, Ajay K. Gopal, Darrell R. Fisher, David G. Coffey, William I. Bensinger, Joseph G. Rajendran, Brian G. Till, Damian J. Green, Pamela S. Becker, Sally J. Lundberg, Leona Holmberg, Manuela Matesan, Margaret E. Nartea, Oliver W. Press
Publikováno v:
Bone Marrow Transplant
To improve disease control without increasing the toxicity of a reduced-intensity allogeneic hematopoietic cell transplantation (HCT) in multiple myeloma (MM), a phase I trial was performed using an antibody-radionuclide conjugate targeting CD45 (90Y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692ec120994027987b1ba9595887f115
https://europepmc.org/articles/PMC8328580/
https://europepmc.org/articles/PMC8328580/
Autor:
Johnnie J, Orozco, Aimee L, Kenoyer, Yukang, Lin, Shyril, O'Steen, Rosario, Guel, Margaret E, Nartea, Alexandra H, Hernandez, Mark D, Hylarides, Darrell R, Fisher, Ethan R, Balkin, Donald K, Hamlin, D Scott, Wilbur, Kelly D, Orcutt, K Dane, Wittrup, Damian J, Green, Ajay K, Gopal, Brian G, Till, Brenda, Sandmaier, Oliver W, Press, John M, Pagel
Publikováno v:
Mol Cancer Ther
Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::47c81591f55a115a393da597affa1abc
https://pubmed.ncbi.nlm.nih.gov/33082277
https://pubmed.ncbi.nlm.nih.gov/33082277
Autor:
Oliver W. Press, Damian J. Green, K. Dane Wittrup, Shyril O'Steen, Kelly Davis Orcutt, Margaret E. Nartea, Ethan R. Balkin, Rosario Guel, Yukang Lin, Alexandra H. Hernandez, Aimee L. Kenoyer, Darrell R. Fisher, Brian G. Till, Brenda M. Sandmaier, Ajay K. Gopal, John M. Pagel, Mark D. Hylarides, Johnnie J. Orozco, D. Scott Wilbur, Donald K. Hamlin
Publikováno v:
PMC
Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad2628a9a42aa6959baa914c543e175
https://hdl.handle.net/1721.1/133436
https://hdl.handle.net/1721.1/133436
Autor:
Margaret E. Nartea, Darrell R. Fisher, Damian J. Green, Johnnie J. Orozco, K. Dane Wittrup, Yukang Lin, D. Scott Wilbur, Kelly Davis Orcutt, Donald K. Hamlin, Mark D. Hylarides, Melilssa L. Comstock, Aimee L. Kenoyer, Brian G. Till, Shyril O'Steen, Oliver W. Press, Ted Gooley, Ajay K. Gopal
Publikováno v:
Blood. 131:611-620
Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical translation. We describe a new PRIT approach for the treatment of multiple myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbc24e8daf037c248de2acd37a1b2a3
https://doi.org/10.1182/blood-2017-09-807610
https://doi.org/10.1182/blood-2017-09-807610
Autor:
Eric Dorman, Manuela Matesan, Rainer Storb, Fatemeh Behnia, Margaret E. Nartea, Hubert Vesselle, Robyn Haaf, Brenda M. Sandmaier, Ted Gooley, Joseph G. Rajendran, Yawen Li, Johnnie J. Orozco, Michelle E. Bouvier, D. Scott Wilbur, Robert Emery, David H. Lewis, Kelsey Baker, Donald K. Hamlin, Erlinda B. Santos, Damian J. Green, Phuong Vo, Roger Wong
Publikováno v:
Transplantation and Cellular Therapy. 27:S54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a821108e49ffca39d679568abd8069b0
https://doi.org/10.1016/s2666-6367(21)00083-x
https://doi.org/10.1016/s2666-6367(21)00083-x